CPMV
What one share of Mosaic Immunoengineering holds
Biological Products, (No Diagnostic Substances)
We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidates and we are pursuing new product candidates and platforms to build a product pipeline based on our deep understanding of immunotherapies.
Mosaic Immunoengineering’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.10 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$1.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.00 | $0.00 | −$0.00 | — | $0.01 |
| 2017 | — | −$0.00 | $0.00 | −$0.00 | — | $0.01 |
| 2018 | — | −$0.00 | $0.00 | −$0.00 | — | $0.01 |
| 2019 | — | −$0.00 | $0.00 | −$0.00 | — | $0.00 |
| 2020 | — | −$0.00 | — | −$0.00 | — | — |
| 2021 | — | −$0.55 | — | −$0.10 | — | −$0.39 |
| 2022 | — | −$0.33 | — | −$0.10 | — | −$0.67 |
| 2023 | — | −$0.14 | — | −$0.07 | — | −$0.81 |
| 2024 | — | −$0.13 | — | −$0.03 | — | −$0.94 |
| 2025 | — | −$0.10 | — | −$0.02 | — | −$1.03 |